吡柔比星\多柔比星治疗非霍奇金淋巴瘤的疗效对比观察
 |
| 第1页 |
参见附件(3038KB，3页)。
[摘要] 目的：了解吡柔比星与多柔比星用于非霍奇金淋巴瘤(NHL)化疗的临床疗效。方法：选择本科2007年7月～2010年6月收治并确诊的NHL患者85例，将其随机分为吡柔比星组48例接受以吡柔比星为主的化疗方案，多柔比星组37例接受以多柔比星为主的化疗方案，对比分析两组的疗效与不良反应。结果：吡柔比星组化疗的有效率为83.3%，多柔比星组为67.6%，两组比较，差异有统计学意义(P<0.05)。多柔比星组发生较多的心脏毒性反应，吡柔比星组则未发生心脏毒性反应，吡柔比星对胃肠道的不良反应较低。结论：与多柔比星为主的方案相比，以吡柔比星为主的化疗方案NHL的疗效更佳，不良反应较小，值得临床推广应用。
[关键词] 吡柔比星；多柔比星；非霍奇金淋巴瘤；化疗
[中图分类号] R733.4 [文献标识码]B[文章编号]1674-4721(2011)07(a)-071-02
Therapeutic effects observation of pirarubicin and doxorubicin on the non-hodgkin lymphoma (NHL) chemotherapy
WANG Fang1, WEI Wei2
1.Medicine Teaching and Research Section of Heze Medical School (On-job Postgraduate of Medical School, Qingdao University), Shandong Province, Heze 274000, China; 2.Gynemetrics Teaching and Research Section of Heze Medical School (On-job Postgraduate of Medical School, Qingdao University), Shandong Province, Heze 274000, China
[Abstract] Objective: To study the therapeutic effects of pirarubicin and doxorubicin for non-hodgkin lymphoma (NHL) chemotherapy. Methods: 85 NHL patients were slected from July 2007 to June 2010 and were divided into pirarubicin group 48 cases and doxorubicin group 37 cases, they were cured by pirarubicin-dominant or doxorubicin-dominant chemotherapy regimen, the therapeutic effects and ADRs of the two groups were compared and analyzed. Results: The effective rate of pirarubicin group was 83.3%, the doxorubicin group was 67.6%, the difference was significant (P<0.05). Doxorubicin group showed more cardiac toxicity and gastrointestinal tract ADR; Pirarubicin group showed less gastrointestinal tract ADRs and no cardiac toxicity. Conclusion: Compares to doxorubicin-dominant regimen, pirarubicin-dominant chemotherapy regimen showes better therapeutic effect, less ADR and clinical potential.
[Key words] Pirarubicin; Doxorubicin; Non-Hodgkin lymphoma (NHL); Chemotherapy
多柔比星也称阿霉素，可抑制肿瘤细胞的DNA聚合酶，也可嵌入到DNA分子中抑制有丝分裂，具有较强的细胞毒作用[1]。但多柔比星因其明显的心脏毒性，在临床中的应用受到较大限制[2]。吡柔比星是多柔比星的四氢吡喃衍生物，脂溶性比多柔比星提高，从而更易通过生物膜，且脱发、心脏毒性与胃肠道等不良反应显著降低[3]。CTOP化疗方案以多柔比星或吡柔比星为主，是治疗非霍奇金淋巴瘤(NHL)的常用方案。为了解吡柔比星与多柔比星用于NHL化疗的临床疗效 ......
您现在查看是摘要介绍页，详见PDF附件(3038KB，3页)。